

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/530,513	08/22/2005		Ralf Dunkel	CS8479/LeA 36187	9581
34469	7590	09/21/2006		EXAMINER	
BAYER C	ROPSCII	ENCE LP		STOCKTON, LA	AURA LYNNE
Patent Depa		•		ART UNIT	PAPER NUMBER
100 BAYER PITTSBUR		15205-9741		1626	TAPER NOMBER
TTTTSDOK	on, TA	13203-3741		DATE MAILED: 09/21/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

•				٤.
		Application No.	Applicant(s)	
		10/530,513	DUNKEL ET AL.	
Office Action	on Summary	Examiner	Art Unit	
		Laura L. Stockton, Ph.D.	1626	
The MAILING DA	NTE of this communication app	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STAT WHICHEVER IS LONG - Extensions of time may be ava after SIX (6) MONTHS from th If NO period for reply is specif - Failure to reply within the set of	SER, FROM THE MAILING DA ailable under the provisions of 37 CFR 1.13 e mailing date of this communication. ed above, the maximum statutory period w or extended period for reply will, by statute, the later than three months after the mailing	IS SET TO EXPIRE 3 MONTH(ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE a date of this communication, even if timely filed	N. nely filed the mailing date of this communication D (35 U.S.C. § 133).	
Status				
2a) ☐ This action is FIN 3) ☐ Since this applica	IAL. 2b)⊠ This ation is in condition for allowar	6, 2005 (Prelim. Amendment). action is non-final. ace except for formal matters, profix parte Quayle, 1935 C.D. 11, 45		
	ande with the produce direct E	x parto Quayro, 1000 O.D. 11, 40	70 O.G. 210.	
4a) Of the above 5) ☐ Claim(s) is 6) ☒ Claim(s) <u>18-25, 2</u> 7) ☒ Claim(s) <u>26 and 3</u>	77 and 29-33 is/are rejected.	vn from consideration.		
Application Papers				
10) The drawing(s) file Applicant may not a Replacement draw	request that any objection to the ding sheet(s) including the correcti	r. epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is objection. See ion is required if the drawing(s) is object.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. §	119			
a)⊠ All b)□ Some 1.□ Certified co 2.□ Certified co 3.⊠ Copies of to application	e * c) None of: ppies of the priority documents ppies of the priority documents he certified copies of the prior from the International Bureau	s have been received in Application ity documents have been received	on No ed in this National Stage	
Attachment(s) 1) Notice of References Cited 2) Notice of Draftsperson's Pa 3) Information Disclosure Stat Paper No(s)/Mail Date 4/6/2	tent Drawing Review (PTO-948) ement(s) (PTO/SB/08)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte	

DETAILED ACTION

Claims 18-33 are pending in the application.

Priority

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Information Disclosure Statement

The Examiner has considered the Information Disclosure Statement(s) filed on April 6, 2005.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the

conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 18-25, 29 and 31-33 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 22-33 and 35-37 of copending Application No. 10/502,994. Although the conflicting claims are not identical, they are not patentably distinct from each other because the

difference between the compounds of the copending application and the compounds instantly claimed is that of a hydrogen versus a methyl group on the nitrogen of the carboxanilide group (secondary amines in the copending application versus the instant claimed tertiary amines). Compare Example 6 on page 41 of the instant application and Example 2 on page 32 of copending Application No. 10/502,994.

It is sufficient if a reference compound is so closely related to claimed compound that a chemist would find the difference an obvious variation; thus, claims are refused where the difference is primarily the one which exists between a secondary and a tertiary amine. Ex parte Bluestone, 135 USPQ 199 (1961).

One skilled in the art would thus be motivated to prepare tertiary amine products of the copending application to arrive at the instant claimed products with the expectation of obtaining additional beneficial

Application/Control Number: 10/530,513

Art Unit: 1626

products which would be useful for controlling undesired microorganisms.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 18-25, 27 and 29-33 are rejected under 35
U.S.C. 103(a) as being unpatentable over Walter et al.
{WO 02/059086} and Elbe et al. {CA 2,474,902}, each
taken alone or in combination with each other and each
in further combination with Kanji et al. {JP

08/176112}. A partial translation of the JP document has been provided and will be referred to hereinafter.

Determination of the scope and content of the prior art (MPEP \$2141.01)

Applicants claim thiazole compounds. Walter et al. (pages 1, 2 and 8-16; and especially compound 4.19 on page 32; compound 7.03 on page 39) and Elbe et al. (pages 1, 4 and 15-30; and especially Example 1 on page 31) teach thiazole compounds which are structurally similar to the instant claimed compounds.

Ascertainment of the difference between the prior art and the claims (MPEP §2141.02)

The difference between the compounds of Walter et al. and the compounds instantly claimed is that the instant claimed compounds are generically described in Walter et al.

The difference between the compounds of Elbe et al.

and the compounds instantly claimed is that of a

hydrogen versus a methyl group on the nitrogen of the

carboxanilide group (secondary amines in Elbe et al. versus the instant claimed tertiary amines).

Further, Kanji et al. teach the interchangeability of the various substituents attached to the nitrogen of the carboxanilide group (see the definition of R1 in Kanji et al. in paragraph [0009]) in thiazole compounds that are useful as microbicidal agents.

Finding of prima facie obviousness--rational and motivation (MPEP \$2142-2413)

The indiscriminate selection of "some" among "many" is prima facie obvious, <u>In re Lemin</u>, 141 USPQ 814 (1964). The motivation to make the claimed compounds derives from the expectation that structurally similar compounds would possess similar activity (e.g., controlling undesired microorganisms).

Further, it is sufficient if a reference compound is so closely related to claimed compound that a chemist would find the difference an obvious variation; thus, claims are refused where the difference is

primarily the one which exists between a secondary and a tertiary amine.

Ex parte Bluestone, 135 USPQ 199 (1961).

One skilled in the art would thus be motivated to prepare products embraced by Walter et al. or prepare a tertiary amino of the compounds taught by Elbe et al., and especially in view of the teachings in Kanji et al., to arrive at the instant claimed products with the expectation of obtaining additional beneficial products which would be useful for controlling undesired microorganisms. Since Walter et al. and Elbe et al. teach thiazole compounds that are structurally similar to each other for controlling undesired microorganisms, the combination of the prior art would also teach the instant claimed invention. The instant claimed invention would have been suggested to one skilled in the art and therefore, the instant claimed invention would have been obvious to one skilled in the art.

Allowable Subject Matter

Page 9

Claims 26 and 28 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura L. Stockton whose telephone number is (571) 272-0710. The examiner can normally be reached on Monday-Friday from 6:15 am to 2:45 pm. If the examiner is out of the Office, the examiner's supervisor, Joseph McKane, can be reached on (571) 272-0699.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the

Application/Control Number: 10/530,513 Page 10

Art Unit: 1626

automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

The Official fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Laura L. Stockton, Ph.D.

Patent Examiner

Art Unit 1626, Group 1620 Technology Center 1600

September 18, 2006